PT - JOURNAL ARTICLE AU - Han-Jun Cho AU - Eui Seok Jeong TI - The characteristics of breast cancer research using big data analysis techniques: recurrence gene study or utilization behavior of hospital but sample statistic error AID - 10.1101/2021.10.07.21264601 DP - 2021 Jan 01 TA - medRxiv PG - 2021.10.07.21264601 4099 - http://medrxiv.org/content/early/2021/10/11/2021.10.07.21264601.short 4100 - http://medrxiv.org/content/early/2021/10/11/2021.10.07.21264601.full AB - Breast cancer is a major cause of female death, and various big data analysis methods have been applied to breast cancer. This study lists cases in which big data analysis was applied to breast cancer research. In addition, statistics and percentages from each specific sample were proposed. However, research on the use of big data has a blind spot that relies on sample characteristics. Therefore, before sampling big data, statistical inference should be discussed more precisely through pre-examination and sample statistical errors should be reduced by professional statistical evaluation of the analysis method.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialIt is not related to clinical trials because it is mainly an open public data study.Funding StatementNo external funds have been raised.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All of them are open access data.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesI checked the contents related to this. https://www.cbioportal.org https://opendata.hira.or.kr/home.do